No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

For years, Alex­ion’s rare-dis­ease port­fo­lio that cen­tered on C5 in­hibitor Soliris has held its grip on a group of prof­itable ul­tra-rare in­di­ca­tions. But chal­lengers are look­ing to take the throne, in­clud­ing No­var­tis and its mid-stage can­di­date that has gar­nered in­ter­est from the FDA.

The FDA on Wednes­day slapped No­var­tis’ ip­ta­co­pan (LNP023) with its break­through tag to treat rare blood dis­or­der parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH), set­ting the drug up for a quick re­view and po­ten­tial chal­lenge to Alex­ion’s Soliris/Ul­tomiris block­buster fran­chise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER